# Hope Medicine

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/hope-medicine
Canonical HTML page: https://getyourbrief.com/entity/hope-medicine

## Timeline

- **2026-03-25**: Phase III Initiation — First patient dosed in the pivotal Phase III clinical trial for endometriosis.
- **2023-06-15**: Phase II Completion — Positive results from Phase II studies demonstrate pain reduction and safety.
- **2019-04-01**: Licensing Agreement — Hope Medicine acquires global rights for HMI-115 from Bayer.

## Recent coverage (2 stories, network-wide)

### Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115
2026-03-25 02:01:10 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Full story: https://getbiobrief.com/story/hope-medicine-phase-3-endometriosis-trial-hmi-115

### Hope Medicine Doses First Phase III Patient in Landmark Endometriosis Trial
2026-03-25 02:00:37 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Full story: https://gethealthbrief.com/story/hope-medicine-phase-iii-endometriosis-trial-commences

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.